Medicines360, a non-profit pharmaceutical company, and Actavis announced a partnership to support Medicines360’s mission to reduce cost as a barrier to accessing women’s birth control. The Medicines360 and Actavis partnership will make the IUD available in the U.S. commercially and at a very low price in U.S. public sector clinics. As part of this agreement, Actavis has licensed the U.S. commercial rights for the Medicines360 LNG20 Intrauterine Device. Medicines360 retains rights to market the product in the U.S. public sector, including family planning clinics that provide services to low-income women. LNG20 is currently in Phase III clinical trials in the United States. Pending U.S. Food and Drug Administration approval, the LNG20 IUD could be launched in the U.S. as early as 2014, the companies said.